Geneticure specializes in personalized medicine for hypertension management by utilizing genetic testing to tailor blood pressure medication recommendations. Their patented test analyzes a sample of DNA obtained from a cheek swab, focusing on 17 genotypes and 11 genes that influence how individuals respond to various hypertension treatments. This approach aims to minimize the trial-and-error process often associated with prescribing blood pressure medications, potentially leading to significant reductions in both systolic and diastolic blood pressure—up to 22% and 39%, respectively. The company’s research indicates that their DNA-guided therapy can also contribute to a 40% reduction in strokes and a 25% decrease in heart attacks, highlighting the potential for improved health outcomes through personalized treatment plans.

The technology behind Geneticure's testing is rooted in a comprehensive understanding of the complex interactions between genetic factors and hypertension. Their methodology goes beyond traditional drug metabolism assessments, incorporating insights into the roles of drug metabolizing enzymes and receptors that are critical to heart, blood vessel, and kidney function. This integrative approach is supported by peer-reviewed research and clinical studies, which validate the effectiveness of their multi-gene panel in optimizing hypertension therapy. By focusing on the unique genetic makeup of each patient, Geneticure aims to enhance the efficacy of hypertension treatments while reducing unnecessary prescriptions and healthcare costs.

United States

Geneticure optimizes prescription drug therapy by using patients’ DNA to guide their blood pressure treatment with a new, actionable tool, supported by clinical evidence to help you provide even better care for your hypertension patients.

Geneticure

Company Details